A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer

Systemic inflammatory response and survival has not been evaluated as a predictive factor of chemotherapy in metastatic pancreatic cancer. The aim of this study was to evaluate the prognostic and predictive value of a baseline Systemic Inflammation Response Index (SIRI) in metastatic pancreatic canc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2020-03, Vol.20 (2), p.254-264
Hauptverfasser:	Pacheco-Barcia, Vilma, Mondéjar Solís, Rebeca, France, Talya, Asselah, Jamil, Donnay, Olga, Zogopoulos, George, Bouganim, Nathaniel, Guo, Katie, Rogado, Jacobo, Martin, Elena, Alcindor, Thierry, Colomer, Ramon
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Cancer therapies Chemotherapy Disease Female Fluorouracil - therapeutic use Gemcitabine Humans Inflammation Irinotecan - therapeutic use Kaplan-Meier Estimate Laboratories Leucovorin - therapeutic use Leukocyte Count Lymphocytes Male Medical prognosis Metastases Metastasis Metastatic pancreatic cancer Middle Aged Monocytes Multivariate analysis Neoplasm Metastasis Neutrophils Oxaliplatin - therapeutic use Paclitaxel Pancreatic cancer Pancreatic Neoplasms - complications Pancreatic Neoplasms - drug therapy Patients Predictive factors Predictive Value of Tests Prognostic factors Progression-Free Survival Statistical analysis Survival Analysis Systemic inflammation Systemic Inflammatory Response Syndrome - complications Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Systemic inflammatory response and survival has not been evaluated as a predictive factor of chemotherapy in metastatic pancreatic cancer. The aim of this study was to evaluate the prognostic and predictive value of a baseline Systemic Inflammation Response Index (SIRI) in metastatic pancreatic cancer. Retrospective study of 164 metastatic pancreatic cancer patients. Associations between overall survival (OS), progression free survival (PFS), chemotherapy and SIRI were analyzed. SIRI is defined by neutrophil x monocyte/lymphocyte 109/L. Median age 66 years. 22 (13%) received mFOLFIRINOX, 59 (36%) gemcitabine + nab-paclitaxel, 40 (24%) gemcitabine, 13 (8%) other regimens and 30 (18%) had not received treatment. Patients with SIRI
ISSN:	1424-3903 1424-3911
DOI:	10.1016/j.pan.2019.12.010